Overview

• Investors of Cassava Sciences, Inc. are encouraged to join class action lawsuits due to alleged false and misleading statements about the company's operations and drug research programs.
• The lawsuits cover a class period from August 18, 2022, to October 12, 2023, with a lead plaintiff deadline set for April 2, 2024.
• Claims include failure to maintain effective data management controls, resulting in data manipulation to overstate the effectiveness of simufilam, Cassava's lead therapeutic drug candidate.
• Rosen Law Firm and Bronstein, Gewirtz & Grossman, LLC, among others, are leading the legal actions, citing significant potential financial and reputational harm to the company.
• The allegations were exacerbated by a report on possible data manipulation involving a researcher associated with simufilam's research program, leading to a significant drop in Cassava's stock price.